IVERIC bio (ISEE) Tops Q3 EPS by 6c; Reports Cash and Cash Equivalents of $242.0M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Iveric Bio Reports Third Quarter 2021 Operational Highlights and Financial Results
November 9, 2021 6:30 AM EST- Zimura® GATHER2 Enrollment Complete; Retention Exceeding Expectations, with Injection Fidelity Rate Target of Greater than 90% -
- Preparations of a New Drug Application (NDA) and Building Commercial Infrastructure are Underway for a Potential Launch of Zimura for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration
- FDA Agreement Under Special Protocol Assessment (SPA) Received for GATHER2 Phase 3 Clinical Trial of Zimura in Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Zimura Phase 3 Clinical Trial for Intermediate AMD to Initiate in 2022... More
